For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Insulin is used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also used to treat people with type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in blood) who need insulin to control their diabetes. Nowadays, Insulin as an important drug is widely used to treat diabetes.
In China and Chinese insulin market, animal insulin, called first generation insulin, has been almost replaced by new type generation insulin. Basing on the trend of China and Chinese insulin industry, this report researches the market of human insulin and insulin analogue in China.
In this report, the statistics of insulin industry is based on Insulin API, the physical features of insulin API is Freeze-dried powder. The weight unite of insulin API weight is Kg in this report.
Scope of the Report:
Insulin API is a relatively concentrated industry in China, The main production are concentrated in Novo Nordisk, Eli Lilly, Sanofi several companies but their products are for their own use. Gan Lee Tonghua Dongbao in recent years to expand production capacity, and they are the main providers of insulin API
The overall domestic policy for the development of insulin API is supported. Local governments have a lot of policies to support the development of the industry. But in recent years environmental protection requirements for the fermentation industry are also getting higher and higher.
The worldwide market for Insulin API is expected to grow at a CAGR of roughly 4.2% over the next five years, will reach 2120 million US$ in 2024, from 1660 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Insulin API in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- Novo Nordisk
- Eli Lilly
- Tonghua Dongbao
- United Laboratory
- Torrent Pharma
- Julphar Diabetes
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- Regular Human Insulin
- Insulin Analogue
Market Segment by Applications, can be divided into
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Insulin API product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Insulin API, with price, sales, revenue and global market share of Insulin API in 2017 and 2018.
Chapter 3, the Insulin API competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Insulin API breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Insulin API market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Insulin API sales channel, distributors, customers, research findings and conclusion, appendix and data source.